Regeneron Shares Slide After Eylea Sales Drop and Regulatory Delay
Regeneron Pharmaceuticals shares declined about 5.24% after the company reported a 10% year-over-year decrease in first-quarter sales of its flagship eye drug Eylea, with Eylea sales of $941 million and headwinds concentrated in the higher-dose Eylea HD. Analysts and the market cited regulatory timing for a second contract manufacturer and a clinic…